Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN · NASDAQ Global Market
+$0.51 today
Vol 0.90M · Avg 0.64M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.6%
avg 14.4%
ROIC
-2.6%
avg 9.4%
ROA
-2.7%
avg 8.1%
Analysis
ROIC is currently the strongest return metric at -2.6% versus its period average of 9.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jack A. Khattar | Founder, President, Chief Executive Officer, Secretary & Director | $1.93M | — | 65 | $1.24M | 2.14% |
Timothy C. Dec | Senior Vice President & Chief Financial Officer | $778,940.00 | — | 67 | $9,682.00 | 0.02% |
Jonathan Rubin | Senior Vice President of Research & Development and Chief Medical Officer | $722,477.00 | — | 65 | $14,016.00 | 0.02% |
Padmanabh Bhatt | Chief Scientific Officer & Senior Vice President of Intellectual Property | $665,175.00 | — | 69 | $24,294.00 | 0.04% |
Frank Mottola | Senior Vice President & Chief Technology Operations Officer | $634,447.00 | — | 54 | $18,440.00 | 0.03% |
Bryan A. Roecklein | Senior VP & Chief Business Officer | — | — | — | $1.24M | 2.14% |
Todd Horich | Senior VP & Chief Commercial Officer | — | — | — | $0.00 | <0.01% |
William Todd Horich | Senior VP & Chief Commercial Officer | — | — | 53 | $0.00 | <0.01% |
Jeff Bozick | Senior Vice President of Supply Chain | — | — | — | — | — |
Kevin T. Anderson | Compliance Officer | — | — | 64 | — | — |
Taylor Raiford | Senior Vice President of Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
31
$19.90M
Net Sentiment
$19.90M
Net selling
Most Active
Khattar Jack A.
11 transactions
1–10 of 31
Analysis
Insiders reported 0 buys worth $0.00 and 31 sells worth $19.90M over the last 12 months. That adds up to net selling of $19.90M. Khattar Jack A. was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +23.8% (15yr)1 analysts |
| Revenue | N/A | N/A | +360.4% | +16.1% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | +24.8% (15yr)2 analysts |
| EBIT | N/A | N/A | N/A | +12.0% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +360.4% over three years. Forward estimates point to Net Income at +24.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.75B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.36B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.03B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.78B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.18B
GRAIL, Inc.
NASDAQ:GRAL
$2.63B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.79B
Bausch Health Companies Inc.
NYSE:BHC
$1.76B
Perrigo Company plc
NYSE:PRGO
$1.37B
Who manages SUPN?
Supernus Pharmaceuticals, Inc. (SUPN) lists 11 active executives. The top listed executive is Timothy C. Dec, Senior Vice President & Chief Financial Officer.
Are SUPN insiders buying or selling?
Recent insider activity shows net selling of $1.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.